June 20, 2019
Baroness Greenfield was invited to speak at Hebrew University in Jerusalem on Thursday 20th June. The talk she gave was titled 'Novel intra-nasal delivery of a synthetic peptide as a treatment for Alzheimer's disease'. Within this presentation Baroness Greenfield discussed Neuro-Bio's research and how we are working towards a new treatment for Alzheimer's Disease.
June 20, 2019
Join Baroness Susan Greenfield at the 1st UK-Israel Dementia Prevention & 27th Tel Aviv University Alzheimer's Disease Conference.
This year the TAU-AD meeting will be part of a joint meeting with the Israel-UK dementia prevention conference. The scope of the meeting is prevention, neurodegeneration and neuroinflammation. Suggested lectures related to these topics as well to other topics in the fields of AD and neurodegeneration are welcome.
June 14, 2019
Neuro-Bio have introduced ‘Star of the Quarter’ in order to recognise those staff members who go above and beyond. This scheme is open to all staff on both the scientific and management teams, and hopes to encourage everyone to perform to the best of their abilities while upholding the Company’s core values… and who doesn’t enjoy a little competition! Our second winner was our Principle Scientist, Henry Tu.
For his Star of the Quarter prize, Henry went to see the show “Harry Potter and the Cursed Child” in London’s West end. The show was divided into two parts, lasting five hours in total. It comprises a mixture of intriguing storytelling, fantastic stage and sound effects and impressive close up magic. For any Harry Potter fan, this was a dream came true and an unforgettable experience. Henry would like to thank the company for giving him this opportunity.
May 8, 2019
Neuro-Bio Ltd appoints Dr. Alex Wilson as Development Director
Oxford, UK; March 2019 – Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company that focuses on a novel approach to treating Alzheimer’s Disease, today announced that it has appointed Dr. Alex Wilson as its new Development Director.
Dr Wilson graduated from the University of Bradford, with a PhD in Psychopharmacology, followed by a 2-year post doc in Parkinson’s Disease at Hammersmith Hospital, utilizing a prototypical small animal PET scanner. He then spent 10 years working in Research and Development at SmithKline Beecham and GlaxoSmithKline, Neuroscience and Neurology centers. In 2007 Dr Wilson moved to Singapore to set up translational medicine capabilities of an SME, CRO, during this time he progressed through C-suite roles in the organisation, and completed an MBA from the University of Chicago, Booth School of Business. Before joining Neuro-Bio, he was the Managing Director for a privately-owned SME in Singapore that focused on in-vitro diagnostic device development using a proprietary affinity reagent approach.
Neuro-Bio’s CEO, Baroness Professor Susan Greenfield said “Now that Neuro-Bio is evolving into a larger company and making the transition from Research to Development in both our biomarker and therapeutic programs, the expertise that Dr Wilson is bringing could not be timelier. We were impressed, not only by his broad pharmaceutical experience, unusually with both biomarker and drug discovery areas, but also by his commercial qualifications. This profile is the perfect fit for ensuring that Neuro-Bio can realise its full potential in progressing towards realistic products for an effective diagnosis and treatment for Alzheimer’s Disease.”
Lord Arbuthnot, Chairman of Neuro-Bio, said, “We are really pleased to welcome Alex to his new role. He brings us the combination of big pharma and SME experience that is exactly what we need at our current stage of development. We have promising data sets showing the effects of a potential therapeutic molecule at a basic research level that may block or significantly retard the progression of the AD pathology. And using the same molecular motifs we have demonstrated a correlation of this structure in blood with CNS pathology, potentially leading to a biomarker / diagnostic. We need to take these highly promising outcomes and translate them into a package of data and reports which, along with other studies, will allow us to provide a regulatory submission for an IND and IVD, respectively. Alex will be ideally placed to take us on this important journey.”
Dr. Wilson said “I am delighted to be able contribute to the work that Neuro-Bio is pioneering. In an era where mankind is living longer, conditions impacting an ever-aging population will only increase in importance. As such, degenerative conditions like Alzheimer’s that rob families of their loved ones well before the end of their natural lives will become more burdensome, both financially and emotionally. Neuro-Bio offers as radical new approach both to early detection and diagnosis, as well as therapeutic intervention, well in advance of the profound neuronal loss and cognitive sequalae that become apparent as the disease progresses. I join the company at an incredibly exciting time when we need to focus our efforts on implementing the preclinical plans that will form the most critical part of our pipeline efforts leading to regulatory submissions”
Dr. Wilson’s pharmaceutical career started at SmithKline Beecham in 1998 where he was a member of the team evaluating pharmacodynamic markers of drug action across the Neuroscience spectrum. Dr. Wilson then moved to the Pain and Epilepsy disease areas in 2000, on the formation of GlaxoSmithKline where he ran various research programs spanning the spectrum of Gene-To-Target, through to Candidate Selection. He was also central to several post candidate selection efforts leading through to clinical trial evaluation. In 2007 Dr. Wilson began development of a translation model platform for a Singapore-based CRO focusing on non-human primate models of disease that spanned the key areas of focus for current medicine, including state of the art molecular imaging capabilities.
Neuro-Bio Ltd (www.neuro-bio.com) is an early stage biopharmaceutical company that is developing novel, effective therapies for neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Motor Neuron diseases. The company was founded in 2013 by Baroness Professor Susan Greenfield based on 40 years of original neuroscience research leading to an exclusive and proprietary approach to developing therapies to arrest the progress of these CNS disorders.
March 25, 2019
New to 2019 - Neuro-Bio have introduced ‘Star of the Quarter’ in order to recognise those staff members who go above and beyond. This scheme is open to all staff on both the scientific and management teams, and hopes to encourage everyone to perform to the best of their abilities while upholding the Company’s core values… and who doesn’t enjoy a little competition! Our first winner was our Head of the Biomarker Team, Paul Morrill.
For his Star of the Quarter prize, Paul visited Pied-a-Tere, a Michelin starred restaurant in Central London. Paul and his guest delighted in the 10 course taster Menu and accompanying wine flight over a 4 and a half hour period which they both enjoyed thoroughly. It was great experience which Paul hopes to repeat in the future and would like to thank the company for giving him this opportunity.
March 22, 2019
On Tuesday 5th March 2019 the British Embassy, Prague hosted an all-day conference ‘Women In Science’ which took place in the Liechtenstein Palace in the centre of Prague. The event was officially represented by the British Embassy in cooperation with the Academy of Sciences of the Czech Republic.
The keynote and panels held female science leaders such as our CEO and Founder Baroness Professor Susan Greenfield, Dame Ottoline Leyser Professor of Plant Development at the University of Cambridge and Director of the Sainsbury Laboratory in Cambridge. Jessica Wade and Physicist from Imperial College London and Dame Jocelyn Bell Burnell an astrophysicist who is best known for her Nobel Prize winning discovery of the pulsar.
With 150 attendees Baroness Greenfield’s speech centred around her personal journey into the sciences and a discussion on the issues that are faced by women that could hinder their career in the scientific field whether this could be the sexism in the company they were work for or their ability to organise child care.
This speech was videoed and will be uploaded when made available.
February 18, 2019
On Monday 4th February Baroness Greenfield spoke at Networking Lunch joint hosted by UKAEA, Neuro-Bio and Aurox at Culham Science Centre. The aim of this event was to introduced Neuro-Bio to other biopharma companies on site and this was a great opportunity for our scientists to work on their networking skills, meet any interested parties and discuss potential partnering or collaboration opportunities.
Dr Leigh Rees from Aurox presented their latest confocal microscopy products while discussing the company history and how it has progressed from manufacturing products for other brands to creating products under their own name. Should you wish to find out more information about Aurox please visit their website: http://www.aurox.co.uk/
February 12, 2019
Neuro-Bio would like to say a massive thank you to Ms Josie Duffy who, with the generous help of family, friends, colleagues, supermarkets and our very own Lord Arbuthnot, has managed to raise over £1,000.
Josie has been a considerable supporter of Neuro-Bio over the years. She holds an annual fundraising event where all proceeds go towards helping Neuro-Bio’s research into Alzheimer’s Disease. She also holds an annual Christmas raffle and tombola and this year she was able to add an auction. These events are a great opportunity, not only to raise funds but also, they allow the staff at a busy children and families service to have some relaxation and socialisation whilst taking advantage of the buffet lunch provided!
February 12, 2019
On Friday 25th January 2019, ERA celebrated their Silver Jubilee with an event at the Royal College of Physicians, London, consisting of a Scientific Meeting followed by a gala dinner. Baroness Greenfield was asked to speak on the future of ‘The Journey of Biopharmaceutical Development’. Her speech focused on the future of biopharmaceuticals and drug development and how this may challenge regulatory paradigms.
ERA Consulting was founded in 1993 by Dr Christopher Holloway, who sadly passed away in 2016, his vision was to support companies in the development of biopharmaceutical products by providing strategic regulatory consulting services. They specialise in the regulatory affairs, consulting services relating to biotech and biological products which has spanned over 20 years of service. Within these years, they have dealt with over 500 products including “natural” biologics, recombinant proteins, gene therapy and viable cell products, including engineered tissues. Many of the products involved were at the “cutting edge” of science and required appropriately innovative strategies.
February 12, 2019
On the 12th – 14 December 2018, Drs Emily Pinkstone and Giovanni Ferrati attended Nottingham University, to complete the in-vivo portion of our study being conducted there, with Prof. Tobias Bast and Adam Seaton. This is a follow up from an in-vivo study conducted earlier in 2018, evaluating the behaviour of rats, following a single injection of the peptide, T30, into the Basal Forebrain.
Our aim of this follow up study is to evaluate the biochemical effects of increasing doses of T30, across different areas of the brain. During our stay in Nottingham we extracted the brains and dissected areas of interest, namely the cerebellum, cortex, subcortex and hippocampus, to bring them back to Neuro-Bio for further in-house analysis.
This analysis will hopefully provide further insight into the role of this toxic peptide in living rodents.
February 12, 2019
Neuro-Bio staff completed another successful training day on the 14th June, with new and familiar faces laughing and learning together.
The seminar lead by Heather Bunny on behalf of Cegos covered many different topics, from Influencing Without Authority to Project Management. Feedback from staff has been very positive with employees saying they have learnt skills that will allow them to become more confident when in new situations and to realise just how important first impressions can be.
We would like to say a big thank you to Heather Bunney, Elliot Wilkins and all the team at Cegos.
February 12, 2019
A Multidisciplinary Approach Reveals an Age-Dependent Expression of a Novel Bioactive Peptide, Already Involved in Neurodegeneration, in the Postnatal Rat Forebrain
The basal forebrain has received much attention due to its involvement in multiple cognitive functions, but little is known about the basic neuronal mechanisms underlying its development, nor those mediating its primary role in Alzheimer’s disease. We have previously suggested that a novel 14-mer peptide, ‘T14’, could play a pivotal role in Alzheimer’s disease, via reactivation of a developmental signaling pathway. In this study, we have characterized T14 in the context of post-natal rat brain development, using a combination of different techniques. Ex-vivo rat brain slices containing the basal forebrain, at different stages of development, were used to investigate large-scale neuronal network activity in real time with voltage-sensitive dye imaging. Subsequent Western blot analysis revealed the expression profile of endogenous T14, its target alpha7 nicotinic receptor and the familiar markers of Alzheimer’s: amyloid beta and phosphorylated Tau. Results indicated maximal neuronal activity at the earliest ages during development, reflected in a concomitant profile of T14 peptide levels and related proteins. In conclusion, these findings show that the peptide, already implicated in neurodegenerative events, has an age-dependent expression, suggesting a possible contribution to the physiological mechanisms underlying brain maturation.
To read the full paper please click here
December 14, 2018
Neuro-Bio was joined this September by three industrial placement students for the academic year 2018-19. Riona Fumi from the University of Leeds, Matthew Passmore from Warwick University and James Gould from York University have been working on three different projects within our Biomarker and Drug Discovery Teams.
Presenting work orally to a critical audience is an important part of scientific research. Therefore, at our final our team meeting of the year, the interns were asked to present an interim report on their projects. Below are brief descriptions of what they outlined:
“For the last month Dr Ferrati and I have been optimising our new experimental set-up, looking at levels of Calcium in ex vivo brain slices using a voltage-sensitive fluorescent dye. The results have been very promising, and exceeded our expectations as to timing: we have therefore been able to fast track and collect data that we are hoping will validate some core ideas” -James Gould
“Today marks the completion of successful assaying of the final cohort of samples from the clinical centre in Melbourne. After countless hours of hard work and determination in the lab, we will now be eagerly awaiting the results from the analysis which must be carried out. More info coming soon!” -Matthew Passmore
“I have been continuing with my project, measuring the levels of beta-amyloid in coronal brain slices of the basal forebrain which have been incubated in T30 for different lengths of time. As a result, I have found a consistent difference between the levels of beta-amyloid across the brain slices rostrally to caudally, and am now doing some research into the anatomy of the basal forebrain to understand what could be causing these differences.” -Riona Fumi
December 5, 2018
In October of this year Neuro-Bio and Aurox met for a joint lunch at our newly refurbished premises at Culham Science Centre in order to discuss and plan a future collaborative agreement to share knowledge, expertise and resources.
Both companies were able to present to one another about the beginnings of their company and what their plans are for the future. Aurox is a laser free confocal microscopy imaging system manufacturer and supplier, supplying the Clarity and Clarity LFC products.
It was a successful event as we determined how we could partner with one another for future mutual progression, this will be a start to many events that will be organised at Culham Science Centre so that we many all benefit from the scientific research that is being.
November 15, 2018
On Wednesday 7th November The Rt Honourable The Lord Arbuthnot and The Baroness Greenfield hosted a truly memorable event at the House of Lords on behalf of Neuro-Bio Ltd. The programme included three after-lunch speeches.
Mr Charlie Holland, introduced Gusbourne, a winery in Appledore Kent that has a single vision: to create English sparkling wines that would be competitive alongside the very finest offerings across the globe. With the help of Charlie Gusbourne has been able to produce some of the most celebrated sparkling wines, winning numerous international awards and becoming the only three-time winner of the IWSC English Wine Producer of the Year. Charlie, the CEO and chief winemaker provided three of his delicious wines for our very appreciative guests.
The second speaker was Dr Anton Hutter, Partner at Venner Shipley, a leading firm of European Intellectual Property Attorneys. Anton has worked closely with Neuro-Bio for over five years, advising on patent strategy and filing.
Dr Hutter shared his recent review of the current patent filings relating to aspects of Alzheimer’s disease- 1,087 refer to familiar features of the late-stage disease beta-amyloid and 269 to tau, - but only two patent families relate to the novel, disruptive approach being developed by Neuro-Bio- both patents belong to Neuro-Bio.
Neuro-Bio patents are supported by three key pillars:
Alzheimer’s Therapy: this encompasses the research focused on a novel drug treatment for patients diagnosed with Alzheimer’s disease;
Alzheimer’s Diagnosis: early diagnosis of a neurodegeneration associated with Alzheimer’s disease using a biomarker well before any symptoms of cognitive decline appear, and;
Cancer: Therapy and Diagnosis: Focusing on a diagnostic kit to detect strongly metastic tumours and a drug that stops cell migration.
The CEO and Founder of Neuro-Bio Baroness Professor Susan Greenfield was the final speaker . Baroness Greenfield has published over 200 papers in peer-reviewed journalsand has been awarded 32 honorary degrees from UK and foreign universities. She has been awarded the ‘Golden Plate Award’ (2003) from the Academy of Achievement, Washington, the L’Ordre National de la Légion d’Honneur (2003), from the French Government and the 2010 Australian Medical Research Society Medal. The speech described the beginnings of Neuro-Bio through the timeline towards its growing success. She described the Neuro-Bio T14 biomarker that will detect deviation from normal levels so that early prevention of the process of could be commenced 20 years before the symptoms may appear. She also shared an update on how Neuro-Bio is developing a new therapeutic drug that could stabilise cell death and one day offer an effective treatment for Alzheimer’s so the symptoms may never appear. Baroness Professor Susan Greenfield said about the event: "I’m delighted to share our latest findings with our shareholders, supporters and scientific colleagues. The company is at an important stage in progressing from basic research to real application of our novel ideas towards a diagnostic and a therapeutic."
We would like to thank The Lord Arbuthnot, Chairman of Neuro-Bio for being our Master of Ceremonies throughout the entire day. Lord Arbuthnot said: “It was good to bring together a group of enthusiastic supporters of Neuro-Bio in the House of Lords. We heard not only from Susan Greenfield about the ground-breaking science being carried on by our high-quality laboratories in Culham, but also from our Patent Agents Venner Shipley, and from Gusbourne Estates, who make outstanding English wine. Anton Hutter, from Venner Shipley who had sponsored the lunch, told us about the impressive families of patents in Neuro-Bio’s name; and Charlie Holland, of Gusbourne who had provided the wine, told us about the way English wine is becoming accepted throughout the world as a worthy rival to champagne. It was a great event!”
The event concluded with discussions and a tour conducted by Lord St John. We would like to say a huge thank you to Venner Shipley and Gusbourne for providing the opportunity for Neuro-Bio to celebrate our pioneering science with all of our supporters.
October 4, 2018
"As well as UKAEA, Culham Science Centre hosts a range of leading scientific companies. One of these is Neuro-Bio, a biotech company with a focus on neurogenerative disease. Scientist, writer and broadcaster Baroness Professor Susan Greenfield (pictured) is CEO of Neuro-Bio, which she founded in 2013. Richard, from the UKAEA communications team, spoke to Susan to find out more about the company’s work. Much of the focus for large companies researching neurodegenerative diseases like Alzheimer’s focuses on alleviating symptoms, with little on halting the progression of it at onset. It’s refreshing then to see a different approach to this being taken by Neuro-Bio – a Culham Science Centre based company since 2014. Led by Susan, the company wants to succeed where others have failed in providing an effective cure for the disease."
To read the full aricle please follow this link: Full Article
September 13, 2018
Last week Neuro-Bio was able to host two important visitors from the United States. Dr Alff of Kairos Ventures came from Beverley Hills in order to discuss our future funding and to talk with the team to fully understand the research taking place here. We also had Dr Singh of UCLA who came to teach two of our resident/senior scientists; Dr Brai and Dr Rotondo the AlphaLISA technique which looks at the interaction of alpha7 receptor with the T14.
To say thank you to Dr Singh for all his hard work over the two weeks he was with us we had a wonderful dinner in Oxford with some of our Neuro-Bio employees.
We would like to thank both of them for taking the time to visit us here at Neuro-Bio and we hope to see them again.
September 10, 2018
Our very own Heather Bunney completed the Snowdon Midnight Challenge on Friday 8th June to raise awareness and funds for a world without dementia.
The team included Lorraine Lloyd, Ana Moura and Heather Bunney, with the team name #walkingformum. This was a very important event considering Ana travelled from Lausanne, Switzerland to be a part of the challenge.
Neuro-Bio staff completed another successful training day on the 14th June, with new and familiar faces laughing and learning together.
They set off at Midnight along the Llanberis Path, easing their way into the challenge. The ascent gradually became steeper and they carried on through the cold night at a steady pace in order for their bodies to acclimatise to the mountain. There was a steep section just before they reached the top of the mountain, before the route evened out gradually and they climbed the final stretch to the summit.
They arrived at 03:30am and then walked ‘steadily’ down for breakfast at 07:00am.
Neuro-Bio wants to say a huge thank you for the support that Heather has provided for us over the years and we hope that you carry on your incredible work.
July 11, 2018
Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease by Emanele Brai, Florian Simon, Antonella Cogoni and Susan A. Greenfield
Despite many studies attempt to identify the primary mechanisms underlying neurodegeneration in 10 Alzheimer’s disease (AD), the key events still remain elusive. We have previously shown that a 11 peptide cleaved from the acetylcholinesterase (AChE) C-terminus (T14) can play a pivotal role as a 12 signaling molecule in neurodegeneration, via its interaction with the α7 nicotinic acetylcholine 13 receptor.
The main goal of this study is to determine whether a cyclized variant (NBP14) of the toxic 14 AChE-derived peptide can antagonize the effects triggered by the linear fragment in modulating well-15 known markers linked to neurodegeneration. We investigate this hypothesis applying NBP14 on ex-16 vivo rat brain slices containing the basal forebrain. Western blot analysis revealed an inhibitory action 17 of NBP14 on naturally occurring T14 peptide, as well as on endogenous amyloid beta, whereas the 18 expression of the nicotinic receptor and phosphorylated Tau was relatively unaffected. These results 19 further confirm the neurotoxic properties of the AChE-peptide and show for the first time in an ex-20 vivo preparation the apparent neuroprotective activity of NBP14, over a protracted period of hours, 21 indicating that T14 pathway may offer a new prospect for therapeutic intervention in AD 22 pathobiology.
To read the full paper please Click here
July 4, 2018
On Thursday 21st June Baroness Greenfield was invited by Vertex, a neighbouring pharmaceutical company here in Oxford, to give a talk on the ‘Neurobiology of Innovation’: the session focused on key questions surrounding the threats and opportunities for creativity in a changing digital environment impacting on the plasticity of the brain and in turn on how we think and feel. The key questions tackled were:
- Can only biological brains be creative?
- What is the physical basis of each individual mind?
- Will the 21st Century brain be more or less creative
- How can an individual be creative?
- What examples of creativity in science research
The answer to the final question was given with an illustration of the disruptive approach of Neuro-Bio to Alzheimer’s disease. Also representing Neuro-Bio at the event were Dr Garcia-Rates, Head of Drug Discovery and Ms Dominique Kleyn, Commercial Director.
May 31, 2018
The Grand opening event was held on 15th May 2018 and was a great opportunity for the company to not only showcase the new, state-of-the art lab and office spaces but also update the shareholders and guests on how far Neuro-Bio has progressed in its novel approach to Alzheimer’s Disease.
The event saw speakers present a wide range of viewpoints, both from scientific and personal and these are detailed below.
Speech provided by Mr Eric Abbott
Eric was a carer for his late-wife who suffered from Alzheimer’s. After her passing he volunteer his time to Alzheimer’s Society after they had helped him so much when his wife was first diagnosed. Eric helps at carer support meetings where they discuss problems they have encountered or require assistance and advice. Eric is also a research volunteer with the Research Network section of the Alzheimer’s Society at their Head Office in London, and provides talks to various organisations about dementia and the effect that it has on the individual.
Interview with Ms Kleyn by Lord Arbuthnot
The interview by Lord Arbuthnot asked Ms Kleyn about what it was like to have a family member that had been diagnosed with Alzheimer's Disease.She discussed how early signs were shown but not attributed to Alzheimer's at the time. With retrospect and further understanding of the Disease she recognises now how early the effects started to show.
Speech provided by Professor Esiri
Professor Margaret Esiri DM is Emeritus Professor of Neuropathology at Oxford University and continues to work part-time on research relating to neurodegeneration and dementia, which she has been interested in for the last 30 years. Earlier in her career she was an MRC Senior Clinical Fellow and then Professor of Neuropathology at Oxford and Honorary Consultant Neuropathologist at the Oxford University Hospitals. Most of her work has been based on the study of autopsied human brain tissue. Her speech summarised the current clinical state of Alzheimer’s Disease and how she came to be involved with Neuro-Bio.
Speech provided by Baroness Greenfield, CBE
Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is British research scientist, author and broadcaster. Baroness Greenfield has published over 200 papers in peer-reviewed journals over the course of her distinguished career. She holds 32 honorary degrees from UK and foreign universities, and has received numerous honours including the Legion d’Honneur from the French Government. Susan also has an Honorary Fellowship from the Royal College of Physicians, American Academy of Achievement Golden Plate Award, and is a member of the Fellowship of the Royal Society of Edinburgh. Baroness Greenfield provided an overview of Neuro-Bio, of what we are striving to achieve and how.
Between speeches audience members were able to listen to videos of Mr Yates AM, Dr Gregory Cole and Dr Richard Mohs. They provided insight on why they chose to support Neuro-Bio Ltd and explaining why an Alzheimer’s treatment is necessary.
Mr Peter Yates is Deputy Chairman of The Myer Family Investments Pty Ltd and a Director of AIA Australia Limited. He is also the Chairman of the Boards of the Royal Children’s Hospital Foundation, the Faculty of Business and Economics at Melbourne University, The Royal Institution of Australia, the Australian Science Media Centre and the Shared Value Project. In June 2011 Queen’s Birthday Honours, Peter was awards as a Member of the Order of Australia for services in the financial services industry, education and a range of arts, science and charitable organisations. If you would like to watch Mr Yates video please visit our YouTube channel, or follow the link here: https://youtu.be/G1FksGyRMCw
Dr Gregory Cole from the David Geffen School of Medicine is currently a Professor of Medicine and Neurology at UCLA where he is also the Associate Director of the UCLA Alzheimer's Center and Associate Director for Research at the Geriatric Research, Education and Clinical Center for the Greater Los Angeles Veterans Administration System. His work for the last two decades has been centred on the production and role of beta amyloid in Alzheimer’s Disease. His work with Neuro-Bio revolves around the proof of concept studies characterising T14 in Alzheimer’s in comparison to control brains.If you would like to watch Dr Cole's video please visit our YouTube Channel, or follow the link here: https://youtu.be/MasnVguC86o
The last video that was viewed was by Dr Richard Mohs who is currently the Chief Scientific Officer for the Global Alzheimer’s Platform Foundation. This organisation focuses on improving the speed and quality of drug development for Alzheimer’s Disease. He also serves as a consultant to academic institutions and biopharmaceutical companies. Mr Mohs is a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation and is a member of the Board of Directors of the Greater Indiana Chapter of the Alzheimer’s Association and is currently on the Science Advisory Board of Neuro-Bio.If you would like to watch Dr Mohs' video please visit our YouTube Channel, or follow the link here:https://youtu.be/fuLOnGWOnck
We would like to say a huge thank you to Venner Shipley for sponsoring the event and for their continued support with our ever-growing patent portfolio. We would also like to thank Creative Catering for providing the food and for their help on the day and Matt Whiteley of Black&Whiteley Photography for capturing the day.
If you would like any further information on the day or would like to request a download of the presentations then please contact Julie Peachey on Julie.email@example.com
May 18, 2018
Whilst in New York, where she was addressing the 2018 Annual Meeting for the American Psychiatric Association in early May, Baroness Greenfield was able to meet up for a lunch with three key investors of Neuro-Bio, Peter Yates, Jim Demetriades and Dave Fuente, none of whom are actually based in the city, but were by sheer happenstance all passing through from Florida, Los Angeles, and Melbourne. The ensuing get-together saw a highly stimulating and successful progression of ideas and plans for the company in developing a biomarker and therapeutic candidate.
Included in the picture with Baroness Greenfield is Kairos Ventures Founder and Managing Partner Jim Demetriades, David Fuente former Chairman and CEO of Office Depot and Director-Investor of Neuro-Bio, and Peter Yates AM Deputy Chairman of the Myer Investments Pty Ltd.
April 23, 2018
Baroness Susan Greenfield paid a visit to Didcot Girls’ School on Wednesday 18th April and gave a talk to Greenfield House members and Didcot Sixth Form. Not only was she able to visit the house in her namesake, but she was able speak about her journey; both professionally and personally. Her key message to the students was that finding their personal identity filled with their own interests and drive is the most important thing in life and she was able to inspire students by describing science as much more than facts; that it is elegant, philosophical in its discovery and can expose dimensions of our human nature. Baroness Greenfield looks forward to maintaining a strong relationship with Didcot Girls’ School and Didcot Sixth Form and was impressed with questions that were asked of her. Here she is pictured with Dr Gohar Khan and Executive Headteacher of Ridgeway Education Trust Mrs Rachael Warwick.
April 16, 2018
The article starts 'What if we have got it wrong on Alzheimer's? Science is about getting it wrong, until you get it right. What if we're refusing to admit we're wrong about a horrifying disease?'
This article shows that people are starting to question the amyloid hypothesis which only proves to strengthen the novel approach that Neuro-Bio is taking to tackle Alzheimer's Disease.
Click HERE to read the whole article on why a new approach to Alzheimer's Disease is necessary.
March 11, 2018
During the second half on March 2018, Professor Susan Greenfield will be visiting Melbourne, sponsored by the University of Melbourne. Whilst in Australia she will meet with our current Australian investors and update them on the rapid pace of progress of Neuro-Bio research. Peter Yates, Deputy Chairman of The Myer Family Investments Ltd, who heads the syndicate of Australian angels and is a long-standing supporter of the Neuro-Bio approach, is also kindly hosting various events where Susan will be presenting to a wider audience.
March 9, 2018
Neuro-Bio recently featured on Oxfordshire's local TV channel. See below for an interview with Baroness Professor Susan Greenfield on Alzheimer's Disease, Series B funding and our new premises.
Published on Feb 6, 2018
Neuro-Bio is an Oxford University spin-out that's pioneering an alternative approach to talking neurodegenerative diseases such as Alzheimer's. Based at the Culham Science Centre the bioteach firm has won millions in funding from a US Company. Our Reporter Alex Meakin has more.
February 7, 2018
As Neuro-Bio continues to grow and we widen the scope and ambitions of our science, more spacious premises have proved an essential to accommodate the increase in researchers and management. Thanks to a very timely injection of funds from some of our Australian angel investors, we have been able to completely reconstruct and radically renovate recently vacated offices, into a mix of office and lab areas. This new space is bespoke and offer state of the art facilities where the whole team can readily interact in an exciting environment.
The company that designed and constructed the new premises is Sanber Ltd, one of the leading laboratory refurbishment and laboratory services installation companies in the UK. Based in Bolton but operating nationwide we provide the complete range of services required for any laboratory refurbishment or development project. They have given us specialist advice for the laboratory project and assistance from concept stage through to commissioning. For more information: http://www.sanberlabservices.co.uk/
Professor Susan Greenfield and Miss Julie Peachey will visit UCB Celltech in Slough at the beginning of February to investigate possible collaborations with their neurodegeneration section and/or investment towards one of Neuro-Bios projects. The two companies originally met at Biotrinity and then again at Genesis 2017 and have had email discussions about possible partnerships for the next phase.
UCB Celltech is a biotechnology business that supports collaboration with academics and biotech companies to investigate new targets for possible development. UCB's goal is to command a leading position in discovering and developing new therapies to treat patients suffering from severe diseases. With a promising pipeline, they focus on neurological and immunological diseases to provide new treatments for specialists and their patients. For more information see: https://www.ucbpharma.co.uk/home